Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

BACKGROUND: PD1 immune checkpoint blockade (αPD1 ICB) has shown unparalleled success in treating many types of cancer. However, response to treatment does not always lead to tumor rejection. While αPD1 ICB relies on cytotoxic CD8(+) T cells, antigen-presenting cells (APCs) at the tumor site are also...

Descripción completa

Detalles Bibliográficos
Autores principales: Schetters, Sjoerd T T, Rodriguez, Ernesto, Kruijssen, Laura J W, Crommentuijn, Matheus H W, Boon, Louis, Van den Bossche, Jan, Den Haan, Joke M M, Van Kooyk, Yvette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371367/
https://www.ncbi.nlm.nih.gov/pubmed/32690667
http://dx.doi.org/10.1136/jitc-2020-000588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371367/
https://www.ncbi.nlm.nih.gov/pubmed/32690667
http://dx.doi.org/10.1136/jitc-2020-000588

Ejemplares similares